Due to its potent but reversible inhibition of cathepsin B endopeptidase activity, together with the improved selectivity for cathepsin B with regard to related peptidases cathepsins H and L [33], compound 17 was chosen for further evaluation of its anti-tumor activity in vitro and in vivo. This evidence concerns the gene LAP3 and neoplasm.